Literature DB >> 17088768

[Vaginal mesh extrusion after transvaginal repair of cystocele using a prosthetic mesh: Treatment and functional outcomes].

X Deffieux1, C Huel, R de Tayrac, J Bottero, R Porcher, A Gervaise, K Bonnet, R Frydman, H Fernandez.   

Abstract

OBJECTIVE: To describe management of vaginal mesh erosion following transvaginal repair of acystocele by placement of a polypropylene mesh. MATERIALS AND
METHOD: Retrospective analysis of 34 consecutive cases of vaginal mesh erosion following transvaginal repair of cystocele using synthetic mesh (Gynemesh or Gynemesh-Soft). We have analyzed the results of both medical and surgical management of this complication. Furthermore, we also assessed sexual and urinary morbidity in women with mesh erosion (n = 34) and in women who had undergone the same procedure but without mesh erosion (n = 111).
RESULTS: Among the 34 patients with vaginal mesh erosion, 23 (68%) have undergone local therapy using Colposeptine (Chlorquinaldol + Promestriène). In 12 (52%) cases no modification of the surface of the erosion was observed. In 6 (26%) cases, a decrease of the surface of the mesh erosion was observed. In 5 (22%) cases the mesh erosion had completely disappeared, with a follow-up of 2 to 9 months. Nineteen symptomatic patients (19/32, 59%) required partial (n = 18) or complete (n = 1) excision of the mesh, associated with vaginal mucosal closure, under general anaesthesia. Duration of operation ranged from 15 to 40 minutes for partial excision of the mesh. This procedure was successful in 14 cases (77%). Four women required repeated resection of the mesh because of recurrence. The incidence of de novo dyspareunia was 12% in patients with vaginal mesh erosion, and 11% in patients without mesh erosion (p = 0.81). The incidence of urge urinary symptoms and voiding dysfunction symptoms was respectively 8% versus 9% (p = 0.95), and 8% versus 10% (p = 0.81) in the 2 groups.
CONCLUSION: Management of vaginal mesh erosion is simple and is associated with a low rate of morbidity. However, patients should be informed that vaginal erosion of the mesh can occur.

Entities:  

Mesh:

Year:  2006        PMID: 17088768     DOI: 10.1016/s0368-2315(06)76463-8

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  7 in total

Review 1.  Update in management of vaginal mesh erosion.

Authors:  Jean-Nicolas Cornu; Laurence Peyrat; François Haab
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 2.  Complications of pelvic organ prolapse surgery and methods of prevention.

Authors:  Renaud de Tayrac; Loic Sentilhes
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

3.  Surgical management of vaginal mesh erosion: an alternative to excision.

Authors:  David Shaker
Journal:  Int Urogynecol J       Date:  2009-10-08       Impact factor: 2.894

4.  Reoperations for mesh-related complications after pelvic organ prolapse repair: 8-year experience at a tertiary referral center.

Authors:  Sophie Warembourg; Majd Labaki; Renaud de Tayrac; Pierre Costa; Brigitte Fatton
Journal:  Int Urogynecol J       Date:  2017-02-01       Impact factor: 2.894

5.  Risk evaluation of smoking and age on the occurrence of postoperative erosions after transvaginal mesh repair for pelvic organ prolapses.

Authors:  Francesco Araco; Gianpiero Gravante; Roberto Sorge; Davide De Vita; Emilio Piccione
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-10

6.  Risk factors for mesh/suture erosion following sacral colpopexy.

Authors:  Geoffrey W Cundiff; Edward Varner; Anthony G Visco; Halina M Zyczynski; Charles W Nager; Peggy A Norton; Joseph Schaffer; Morton B Brown; Linda Brubaker
Journal:  Am J Obstet Gynecol       Date:  2008-10-31       Impact factor: 8.661

7.  Surgical treatment of persistent vaginal granulation tissue using CO(2) laser vaporization under colposcopic and laparoscopic guidance.

Authors:  Benjamin J Steinberg; Tiffany Mapp; Saifuddin Mama; Karolynn T Echols
Journal:  JSLS       Date:  2012 Jul-Sep       Impact factor: 2.172

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.